Roundhill Investments has launched OZEM, an actively managed ETF centered on the expanding weight loss drug market. This ETF features #InnoventBiologics as one of its holdings, representing 5% of the portfolio. This strategic inclusion reflects a balanced approach to capturing growth from both established leaders and innovative entrants in the sector. We're proud of our team's hard work and stand behind mazdutide's success in clinical trials. With Goldman Sachs projecting that the obesity treatment market could reach $100 billion by 2030, OZEM aims to leverage a broad spectrum of opportunities within this growing field. To gain deeper insights into this new ETF, watch the full interview here: https://lnkd.in/gMptMerH #Mazdutide #WeightLoss
Innovent Biologics
制药业
Suzhou,Jiangsu 23,096 位关注者
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.
关于我们
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 11 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
- 网站
-
http://www.innoventbio.com
Innovent Biologics的外部链接
- 所属行业
- 制药业
- 规模
- 5,001-10,000 人
- 总部
- Suzhou,Jiangsu
- 类型
- 上市公司
- 创立
- 2011
- 领域
- Biologics Manufacturing、Monoclonal Antibodies、Biosimilars和Novel Drugs
地点
Innovent Biologics员工
动态
-
Exciting news! Innovent's PD-1/IL-2α bispecific antibody fusion protein (IBI363) has earned FDA Fast Track Designation, marking a significant step forward in the fight against unresectable advanced or metastatic melanoma for patients who have progressed after PD-1/L1 inhibitor therapy. Ongoing trials in China, the U.S. and Australia are actively assessing the efficacy and safety of IBI363 in tackling advanced malignant tumors. https://lnkd.in/gp7Sf49x #InnoventBiologics #Oncology
-
-
Mazdutide (GLP-1R/GCGR dual agonist) will have multiple clinical study results presented at the EASD 60th Annual Meeting in Madrid from September 9-13, including the key Phase 3 DREAMS-2 study in Chinese adults with type 2 diabetes. We're excited to share these promising developments with the broader scientific community. Details on where to find us below:https://lnkd.in/gQ96K6t5 #InnoventBiologics #EASD2024
-
-
Our team will be giving nearly 20 clinical data presentations on our novel oncology molecules, including six oral presentations, at the upcoming WCLC in San Diego and ESMO in Barcelona this September. We look forward to sharing our latest advancements in cancer research with the global medical community. Details on where to find us below. Come say hello! https://lnkd.in/gcQPsZrS #InnoventBiologics #WCLC24 #ESMO24 #oncology
-
-
We're excited to share our strong 2024 interim results, highlighting key advancements in both oncology and biomedicine pipelines, alongside remarkable progress in our overall performance. These achievements demonstrate our commitment to sustainable growth and global innovation. We're grateful to our dedicated team, partners, and stakeholders for helping us deliver health solutions to more patients worldwide. https://lnkd.in/dNUvwae6
-
-
Celebrating 13 Years of Innovation at Innovent! What a journey it's been! Over the past 13 years, we've brought 11 groundbreaking therapies to market, advancing the fields of oncology, immunology, cardiovascular and metabolism (CVM), and ophthalmology. This success wouldn't have been possible without our incredible teams, dedicated partners, supportive community, and of course, the patients who inspire us every day. Together, we're pushing the boundaries of science and creating a brighter, healthier future for all. Here's to many more years of discovery and impact! #InnoventBiologics #Teamwork
-
-
We're proud to announce that Dupert® (fulzerasib) has been approved as China's first KRAS G12C inhibitor for advanced NSCLC patients with the KRAS G12C mutation who have undergone prior systemic therapy! NSCLC makes up roughly 85% of lung cancer cases, with KRAS mutations detected in 15-20% of them. This approval marks Dupert® as Innovent's eleventh product in our portfolio, advancing our mission to deliver affordable, high-quality biopharmaceuticals to patients worldwide. https://lnkd.in/gHHddp_z #InnoventBiologics #HealthCare
-
-
We are thrilled to announce that Innovent and Sanegene Bio have successfully dosed the first participant in a Phase 1 first-in-human clinical trial of IBI3016 (SGB-3908), an siRNA drug candidate targeting angiotensinogen (AGT) for hypertension treatment. Hypertension, affecting over 1 billion people globally, poses serious health risks including cardiovascular diseases, kidney damage, and impaired vision. As global hypertension rates rise, IBI3016 promises a groundbreaking solution for better health outcomes. https://lnkd.in/gs8gPgaj #InnoventBiologics #HealthCare
-
-
We are excited to announce that the NDA for mazdutide has been accepted by China's NMPA for the treatment of type 2 diabetes! As the first GLP-1R/GCGR dual agonist to succeed in Phase 3 trials for T2D, mazdutide promises to offer a new treatment option with comprehensive advantages in glycemic control, weight reduction, and wide-ranging metabolic benefits. https://lnkd.in/gPec_3XE #InnoventBiologics #Mazdutide
-